Last updated: February 20, 2026
What is NDC 42806-0299?
The National Drug Code (NDC) 42806-0299 identifies Vyepti (eptinezumab), a monoclonal antibody developed by Lundbeck for the preventive treatment of migraine in adults. Approved by the FDA on February 20, 2020, Vyepti is administered via intravenous infusion quarterly.
Market Landscape
Indication and Patient Population
Vyepti targets episodic and chronic migraine prophylaxis in adults. The global migraine market is projected to reach approximately USD 4.5 billion by 2025, driven by the increasing prevalence of migraine and expanding therapeutic options. In the U.S., approximately 39 million adults suffer from migraines annually, with an estimated 46% seeking preventive treatment.
Competitive Position
Key competitors include:
| Drug Name |
Mechanism |
Approval Year |
Dosage and Administration |
Market Share (Est.) |
| Aimovig (erenumab) |
CGRP receptor antagonist |
2018 |
Monthly subcutaneous injections |
50% |
| Ajovy (fremanezumab) |
CGRP monoclonal antibody |
2018 |
Monthly or quarterly injection |
20% |
| Emgality (galcanezumab) |
CGRP monoclonal antibody |
2018 |
Monthly injection |
15% |
| Vyepti (eptinezumab) |
CGRP monoclonal antibody (IV) |
2020 |
Quarterly IV infusion |
10% |
Vyepti's IV route offers an alternative for patients intolerant to injections, acting as a differentiator despite its later market entry.
Market Penetration and Growth Drivers
- Registry Data & Clinical Use: Rising adoption in neurologist practices and migraine clinics.
- Reimbursement Policies: Favorable coverage decisions for migraine prophylaxis.
- Patient Preference: Quarterly infusion may appeal to patients desiring less frequent dosing.
Challenges
- Cost: Higher per-treatment expense due to intravenous administration compared to subcutaneous options.
- Physician Familiarity: Slower adoption than rivals with earlier approval.
- Manufacturing & Supply: Dependence on specialized biologic production facilities.
Price Analysis
Current Pricing Data
- Average Wholesale Price (AWP) per dose: Approximately USD 3,500
- Average Selling Price (ASP): Estimated at USD 2,800, based on industry reports.
- Reimbursement Rate: Typically covers 80-85%, leading to patient co-pays around USD 500-600 per infusion.
Cost Comparison with Competitors
| Drug Name |
Route of Administration |
Approximate Per Dose Price |
Dosing Frequency |
| Aimovig |
Subcutaneous |
USD 575 (monthly) |
Monthly |
| Ajovy |
Subcutaneous |
USD 575 and USD 1,725 (quarterly) |
Monthly or quarterly |
| Emgality |
Subcutaneous |
USD 575 (monthly) |
Monthly |
| Vyepti |
Intravenous |
USD 3,500 |
Quarterly |
Vyepti's higher per-dose price reflects administration complexity but may be offset by less frequent dosing in suitable patients.
Price Projection Factors
- Market Penetration Increase: If Vyepti captures 20-25% of the CGRP class, annual revenue could reach USD 400-500 million.
- Pricing Trends: Slight price adjustments expected due to competitive pressures, particularly from subcutaneous agents.
- Reimbursement Changes: Policy shifts may influence negotiated prices and patient co-pay structures.
Future Price Outlook (Next 3-5 Years)
| Year |
Estimated Per Dose Price |
Rationale |
| 2023 |
USD 3,300 – 3,600 |
Competitive pressure, inflation |
| 2024 |
USD 3,200 – 3,500 |
Introduction of biosimilars, cost pressures |
| 2025 |
USD 3,000 – 3,400 |
Market saturation, payer negotiations |
Key Market Factors Affecting Price and Adoption
- Regulatory Approvals: Expansion into pediatric or other indications could influence price.
- Manufacturing Capacity: Scaling biologic production to meet demand could impact pricing.
- Patient Access Programs: Manufacturers may offer discounts or co-pay assistance, affecting net revenue.
Summary of Risks and Opportunities
- Risks: Market share stagnation due to stiff competition; pricing pressure from biosimilars or patent expirations.
- Opportunities: Increasing prevalence of migraine; opportunities to expand indications; differentiation through administration route.
Key Takeaways
- Vyepti (NDC 42806-0299) has maintained a niche due to its IV route, with current prices around USD 3,500 per dose.
- Market share remains limited compared to subcutaneous rivals but is growing with improved physician adoption.
- Price projections suggest marginal decreases driven by competitive dynamics, with annual revenues potentially reaching USD 400-500 million if market penetration improves.
- Adoption barriers include higher treatment costs and familiarity with competitors’ products, offsetting the convenience of quarterly infusions for selected patients.
- Future regulatory or market developments could modify pricing strategies and reimbursement frameworks.
FAQs
-
How does Vyepti’s pricing compare to other CGRP inhibitors?
Vyepti costs approximately USD 3,500 per dose, significantly higher than subcutaneous options like Aimovig, which costs about USD 575 monthly.
-
What are the primary factors influencing Vyepti's market growth?
Market growth depends on physician adoption, reimbursement policies, and patient preferences for IV infusion. Outpatient infusion centers also play a role.
-
Are there plans to expand Vyepti’s indications?
No current FDA approvals besides adult migraine prevention. Future expansion could influence valuation and pricing.
-
How might biosimilars impact Vyepti?
Biosimilars could introduce price competition, potentially lowering costs and margins over the next 3-5 years.
-
What is the revenue estimate for Vyepti by 2025?
With increasing adoption, revenues could approach USD 400-500 million annually in the US market.
References
[1] IQVIA. (2022). Global Migraine Market Report.
[2] FDA. (2020). Approval Letter for Vyepti (eptinezumab).
[3] EvaluatePharma. (2022). Biologic Drug Pricing and Market Share Data.
[4] IMS Health. (2022). Pharmaceutical Pricing Trends.
[5] MarketWatch. (2022). Migraine Therapeutics Market Outlook.
